| Year |
Citation |
Score |
| 2024 |
Fatima N, Shen Y, Crassini K, Burling O, Thurgood L, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells . Leukemia & Lymphoma. 1-13. PMID 38227293 DOI: 10.1080/10428194.2023.2300055 |
0.817 |
|
| 2023 |
Anderson MA, Bennett R, Badoux X, Best G, Chia N, Cochrane T, Cull G, Crassini K, Harrup R, Jackson S, Kuss B, Lasica M, Lew TE, Marlton P, Opat S, ... ... Mulligan SP, et al. Chronic lymphocytic leukaemia Australasian consensus practice statement. Internal Medicine Journal. 53: 1678-1691. PMID 37743239 DOI: 10.1111/imj.16207 |
0.751 |
|
| 2021 |
Shen Y, Coyle L, Kerridge I, Stevenson W, Arthur C, McKinlay N, Fay K, Ward C, Greenwood M, Best OG, Solterbeck A, Guminski A, Shumack S, Mulligan SP. Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. Ejhaem. 3: 129-138. PMID 35846218 DOI: 10.1002/jha2.366 |
0.738 |
|
| 2021 |
Fatima N, Shen Y, Crassini K, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. Ejhaem. 2: 81-93. PMID 35846080 DOI: 10.1002/jha2.160 |
0.839 |
|
| 2021 |
Almazi JG, Alomari M, Belov L, Best OG, Shen Y, Graham ME, Mulligan SP, Christopherson RI. Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines. Nucleosides, Nucleotides & Nucleic Acids. 1-7. PMID 34886743 DOI: 10.1080/15257770.2021.2013500 |
0.654 |
|
| 2021 |
Do C, Best OG, Thurgood L, Hotinski A, Apostolou S, Mulligan SP, Lower K, Kuss B. Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. British Journal of Haematology. 193: 556-560. PMID 33851417 DOI: 10.1111/bjh.17394 |
0.612 |
|
| 2020 |
Fatima N, Crassini KR, Thurgood L, Shen Y, Christopherson RI, Kuss B, Mulligan SP, Best OG. Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. Cancer Drug Resistance (Alhambra, Calif.). 3: 532-549. PMID 35582439 DOI: 10.20517/cdr.2019.111 |
0.807 |
|
| 2020 |
Shen Y, Crassini K, Fatima N, O'Dwyer M, O'Neill M, Christopherson RI, Mulligan SP, Best OG. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Advances. 4: 5093-5106. PMID 33085757 DOI: 10.1182/bloodadvances.2019001369 |
0.833 |
|
| 2020 |
Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leukemia Research. 97: 106432. PMID 32911375 DOI: 10.1016/J.Leukres.2020.106432 |
0.412 |
|
| 2020 |
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo J, Czyz J, et al. A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY. Blood. PMID 32731259 DOI: 10.1182/Blood.2020006844 |
0.391 |
|
| 2020 |
Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, Wight J, Ku M, Quach H, Gasiorowski R, Polizzotto MN, Prince HM, Mulligan S, Tam CS, Gregory G, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Internal Medicine Journal. PMID 32415723 DOI: 10.1111/Imj.14859 |
0.378 |
|
| 2019 |
Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, et al. Ibrutinib associated invasive fungal diseases in patients with CLL and non-Hodgkin lymphoma: an observational study. Mycoses. PMID 31520441 DOI: 10.1111/Myc.13001 |
0.346 |
|
| 2019 |
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, et al. Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology. PMID 31512258 DOI: 10.1002/Ajh.25638 |
0.412 |
|
| 2019 |
Crassini K, Stevenson WS, Mulligan SP, Best OG. Molecular pathogenesis of chronic lymphocytic leukaemia. British Journal of Haematology. PMID 31364161 DOI: 10.1111/Bjh.16102 |
0.802 |
|
| 2019 |
Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, et al. Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab. Blood. PMID 30842083 DOI: 10.1182/Blood-2018-08-870238 |
0.4 |
|
| 2019 |
Shen Y, Crassini K, Sandhu S, Fatima N, Christopherson RI, Mulligan SP, Best OG. Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. Leukemia & Lymphoma. 1-12. PMID 30648436 DOI: 10.1080/10428194.2018.1542148 |
0.833 |
|
| 2019 |
Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, et al. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood. 133: 494-497. PMID 30455380 DOI: 10.1182/Blood-2018-03-839688 |
0.327 |
|
| 2019 |
Barr PM, Munir T, Brown JR, O'Brien SM, Barrientos JC, Reddy NM, Coutre S, Tam CSL, Mulligan SP, Jäger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, et al. Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. Journal of Clinical Oncology. 37: 7510-7510. DOI: 10.1200/Jco.2019.37.15_Suppl.7510 |
0.323 |
|
| 2019 |
Fatima N, Shen Y, Crassini KR, Iwanowicz E, Christopherson R, Best G, Mulligan SP. TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status Blood. 134: 1735-1735. DOI: 10.1182/Blood-2019-132160 |
0.801 |
|
| 2019 |
Shen Y, Crassini KR, Fatima N, Christopherson R, Mulligan SP, Best OG. Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment Blood. 134: 5443-5443. DOI: 10.1182/Blood-2019-130082 |
0.838 |
|
| 2019 |
Barr PM, Tedeschi A, Munir T, Hillmen P, Woyach J, Byrd JC, Ghia P, Mulligan S, Dai S, Amaya-Chanaga C, Dean JP, o'Brien SM. Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Blood. 134: 3054-3054. DOI: 10.1182/Blood-2019-123327 |
0.317 |
|
| 2018 |
Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, et al. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 30249389 DOI: 10.1016/J.Clml.2018.08.007 |
0.432 |
|
| 2018 |
Crassini K, Shen Y, O'Dwyer M, O'Neill M, Christopherson R, Mulligan S, Best OG. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. British Journal of Haematology. PMID 29978459 DOI: 10.1111/Bjh.15447 |
0.836 |
|
| 2018 |
Crassini KR, Best OG, Mulligan SP. Immune failure, infection and survival in chronic lymphocytic leukemia. Haematologica. 103: e329. PMID 29970494 DOI: 10.3324/Haematol.2018.196543 |
0.778 |
|
| 2018 |
Crassini K, Pyke T, Shen Y, Stevenson WS, Christopherson RI, Mulligan SP, Best OG. Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. Leukemia & Lymphoma. 1-12. PMID 29911936 DOI: 10.1080/10428194.2018.1455974 |
0.827 |
|
| 2018 |
Crassini K, Shen Y, Stevenson WS, Christopherson R, Ward C, Mulligan SP, Best OG. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. British Journal of Haematology. PMID 29767411 DOI: 10.1111/Bjh.15282 |
0.831 |
|
| 2018 |
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017766840. PMID 29715056 DOI: 10.1200/Jco.2017.76.6840 |
0.43 |
|
| 2018 |
Crassini KR, Zhang E, Balendran S, Freeman JA, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson WS, Mulligan SP. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. British Journal of Haematology. PMID 29468645 DOI: 10.1111/Bjh.15146 |
0.783 |
|
| 2018 |
Mulcahy A, Mulligan SP, Shumack SP. Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia. Leukemia & Lymphoma. 59: 578-582. PMID 28771053 DOI: 10.1080/10428194.2017.1349903 |
0.335 |
|
| 2018 |
Crassini KR, Shen Y, Stevenson WS, Mulligan SP, Best OG, Christopherson R. mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node Blood. 132: 1850-1850. DOI: 10.1182/Blood-2018-99-118264 |
0.805 |
|
| 2018 |
Mulligan SP, Freeman JA, Badoux X, Eek R, Cull G, Mackinlay NJ, Murphy NE, Carradice DP, Solterbeck AC, Best OG, Tam CS, Kuss BJ. Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy Blood. 132: 3144-3144. DOI: 10.1182/Blood-2018-99-116287 |
0.621 |
|
| 2018 |
Shen Y, Crassini KR, O'Dwyer ME, O'Neill MF, Christopherson R, Mulligan SP, Best OG. The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment Blood. 132: 1870-1870. DOI: 10.1182/Blood-2018-99-115574 |
0.839 |
|
| 2018 |
Rizwan N, Shen Y, Iwanowicz E, Mulligan SP, Crassini KR, Christopherson R, Best OG. ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment Blood. 132: 3145-3145. DOI: 10.1182/Blood-2018-99-115555 |
0.834 |
|
| 2018 |
Mulligan SP, Gill D, Cull G, Berkahn L, Simpson D, Campbell P, Harrup RA, Mackinlay NJ, Tam CS, Badoux X, Best OG, Kuss BJ. Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status Blood. 132: 4432-4432. DOI: 10.1182/Blood-2018-99-114064 |
0.625 |
|
| 2018 |
Solman IG, Taylor M, You H, O'Brien SM, Mulligan SP, Byrd JC, Dean JP, James DF, Mongan A. Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Blood. 132: 3114-3114. DOI: 10.1182/Blood-2018-99-110848 |
0.407 |
|
| 2017 |
Shen Y, Best OG, Mulligan SP, Christopherson RI. Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. Leukemia & Lymphoma. 1-11. PMID 29164976 DOI: 10.1080/10428194.2017.1403598 |
0.633 |
|
| 2017 |
Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, ... ... Mulligan S, et al. Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry. Part B, Clinical Cytometry. PMID 29024461 DOI: 10.1182/Blood.V126.23.4146.4146 |
0.367 |
|
| 2017 |
Belov L, Hallal S, Matic K, Zhou J, Wissmueller S, Ahmed N, Tanjil S, Mulligan SP, Best OG, Simpson RJ, Christopherson RI. Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays. Methods in Molecular Biology (Clifton, N.J.). 1619: 263-301. PMID 28674892 DOI: 10.1007/978-1-4939-7057-5_20 |
0.657 |
|
| 2017 |
Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. Leukemia. PMID 28592889 DOI: 10.1038/Leu.2017.175 |
0.364 |
|
| 2017 |
Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. PMID 28373262 DOI: 10.1182/Blood-2016-12-737346 |
0.337 |
|
| 2017 |
Lee A, Sandhu S, Imlay-Gillespie L, Mulligan S, Shumack S. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. The Australasian Journal of Dermatology. PMID 28295171 DOI: 10.1111/Ajd.12615 |
0.395 |
|
| 2017 |
Montillo M, O'Brien S, Tedeschi A, Byrd JC, Dearden C, Gill D, Brown JR, Barrientos JC, Mulligan SP, Furman RR, Cymbalista F, Plascencia C, Chang S, Hsu E, James DF, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer Journal. 7: e524. PMID 28157216 DOI: 10.1038/Bcj.2017.5 |
0.395 |
|
| 2017 |
Ruchlemer R, Ami RB, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino S, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill BT, Mulligan S, Nijland M, et al. Ibrutinib: A Risk Factor for Invasive Fungal Infections? Blood. 130: 4323-4323. DOI: 10.1182/Blood.V130.Suppl_1.4323.4323 |
0.372 |
|
| 2017 |
Sandhu S, Mulligan S, Best G. The therapeutic potential of dual inhibition of MEK1/2 and akt in chronic lymphocytic leukaemia (CLL) Pathology. 49: S110-S111. DOI: 10.1016/J.Pathol.2016.12.320 |
0.439 |
|
| 2017 |
Wierda W, Chyla B, Eichhorst B, Schetelig J, Munir T, Hillmen P, Seymour JF, Roberts AW, Coutre S, Jurczak W, Mulligan SP, Wendtner C, Davids M, Böettcher S, Cerri E, et al. Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial Clinical Lymphoma Myeloma and Leukemia. 17: S303. DOI: 10.1016/J.Clml.2017.07.098 |
0.344 |
|
| 2017 |
Montillo M, Byrd J, Hillmen P, O'Brien S, Barrientos J, Reddy N, Coutre S, Tam C, Mulligan S, Jaeger U, Barr P, Furman R, Kipps T, Thornton P, Moreno C, et al. LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP Hematological Oncology. 35: 235-236. DOI: 10.1002/Hon.2438_98 |
0.343 |
|
| 2016 |
Li J, Best OG, Mulligan SP, Fernando SL. Serum from a subset of patients with chronic lymphocytic leukaemia and large local reactions to mosquito bites significantly induces upregulation of CD63 surface expression in atopic basophils. Pathology. 48: S57. PMID 27773070 DOI: 10.1016/J.Pathol.2015.12.141 |
0.352 |
|
| 2016 |
Li J, Best OG, Mulligan SP, Fernando SL. Exploring the mechanisms of large local reactions to insect bites in patients with chronic lymphocytic leukaemia. Pathology. 48: S43. PMID 27773034 DOI: 10.1016/J.Pathol.2015.12.105 |
0.618 |
|
| 2016 |
Crassini K, Shen Y, Mulligan S, Giles Best O. Modeling the chronic lymphocytic leukemia microenvironment in vitro. Leukemia & Lymphoma. 1-14. PMID 27756161 DOI: 10.1080/10428194.2016.1204654 |
0.765 |
|
| 2016 |
Mulligan SP, Ward CM, Whalley D, Hilmer SN. Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. British Journal of Haematology. PMID 27611114 DOI: 10.1111/Bjh.14321 |
0.431 |
|
| 2016 |
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. The Lancet. Oncology. PMID 27178240 DOI: 10.1016/S1470-2045(16)30019-5 |
0.457 |
|
| 2016 |
Li J, Best OG, Mulligan SP, Fernando SL. Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors. Leukemia & Lymphoma. 1-4. PMID 27104626 DOI: 10.3109/10428194.2016.1173208 |
0.635 |
|
| 2016 |
Belov L, Matic KJ, Hallal S, Best OG, Mulligan SP, Christopherson RI. Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. Journal of Extracellular Vesicles. 5: 25355. PMID 27086589 DOI: 10.3402/Jev.V5.25355 |
0.627 |
|
| 2016 |
Badoux X, Mulligan S, Gabrielli S, Zhu Y, Bressel M, Best G, Hayes M, Iulio JD, Kuss B. Molecular Profiling of elderly patients receiving frontline fludarabine-based chemo-immunotherapy in the ALLG CLL5 study Leukemia & Lymphoma. 56: 120-121. PMID 26332288 DOI: 10.3109/10428194.2015.1080893 |
0.319 |
|
| 2016 |
Gottlieb D, Aurran T, Tam CS, Sartor M, Letestu R, Carney D, Cull G, Levy V, Leblond V, Bene MC, Budniak A, Mulligan S, Cymbalista F. Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO) Blood. 128: 2053-2053. DOI: 10.1182/Blood.V128.22.2053.2053 |
0.392 |
|
| 2015 |
Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, ... ... Mulligan S, et al. A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study. Leukemia. PMID 26639181 DOI: 10.1038/Leu.2015.313 |
0.369 |
|
| 2015 |
Kaufman K, Jenkins Y, Alomari M, Mirzaei M, Best O, Pascovici D, Mactier S, Mulligan S, Haynes P, Christopherson RI. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget. PMID 26556860 DOI: 10.18632/Oncotarget.5715 |
0.676 |
|
| 2015 |
Huang PY, Mactier S, Armacki N, Best OG, Belov L, Kaufman KL, Pascovici D, Mulligan SP, Christopherson RI. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-29. PMID 26422656 DOI: 10.3109/10428194.2015.1094692 |
0.667 |
|
| 2015 |
Crassini K, Mulligan SP, Best OG. Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World Journal of Clinical Cases. 3: 694-704. PMID 26301230 DOI: 10.12998/Wjcc.V3.I8.694 |
0.831 |
|
| 2015 |
Sandhu S, Mulligan SP. Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia. Haematologica. 100: 411-4. PMID 25828085 DOI: 10.3324/Haematol.2015.124107 |
0.412 |
|
| 2015 |
Crassini K, Stevenson WS, Mulligan SP, Best OG. The MEK1/2 inhibitor, MEKi-1, induces cell death in Chronic Lymphocytic Leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leukemia & Lymphoma. 1-29. PMID 25804768 DOI: 10.3109/10428194.2015.1032963 |
0.822 |
|
| 2015 |
Hamad N, Kliman D, Best OG, Caramins M, Hertzberg M, Lindeman R, Porter R, Mulligan SP. Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management. British Journal of Haematology. 168: 350-60. PMID 25256787 DOI: 10.1111/Bjh.13134 |
0.608 |
|
| 2015 |
Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jäger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, et al. Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 33: 7012-7012. DOI: 10.1200/Jco.2015.33.15_Suppl.7012 |
0.351 |
|
| 2015 |
Sandhu S, Gill D, Turner PD, Renwick WEP, Latimer M, Mackinlay N, Berkahn L, Simpson DR, Campbell P, Forsyth C, Cull G, Harrup R, Best G, Bressel M, Di Iulio J, ... ... Mulligan S, et al. Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial Blood. 126: 5295-5295. DOI: 10.1182/Blood.V126.23.5295.5295 |
0.312 |
|
| 2015 |
Sandhu S, Mackinlay N, Coyle L, Best G, Mulligan S. Detailed Long-Term Follow up of Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Patients in the Australasian Leukemia and Lymphoma Group (ALLG) CLL5 Trial; Data on 17 (15% of Total Cohort) Patients from a Single-Institution Blood. 126: 5294-5294. DOI: 10.1182/Blood.V126.23.5294.5294 |
0.413 |
|
| 2015 |
Imlay-Gillespie L, Kliman DS, Wong K, Arthur C, Coyle L, Fay K, Kerridge IH, Mackinlay N, Mulligan S, Stevenson W, Ward CM, Greenwood M. Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders Blood. 126: 5038-5038. DOI: 10.1182/Blood.V126.23.5038.5038 |
0.464 |
|
| 2015 |
Kliman DS, Imlay-Gillespie L, McIlroy K, Gill A, Arthur C, Coyle L, Fay K, Kerridge IH, Mackinlay N, Mulligan S, Stevenson WS, Ward CM, Greenwood M. Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma Blood. 126: 2656-2656. DOI: 10.1182/Blood.V126.23.2656.2656 |
0.376 |
|
| 2015 |
Imlay-Gillespie L, Dix C, McEwan A, Wong K, Figtree M, Arthur C, Coyle L, Fay K, Greenwood M, Mackinlay N, Mulligan S, Stevenson W, Ward CM, Kerridge IH. Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study Blood. 126: 2108-2108. DOI: 10.1182/Blood.V126.23.2108.2108 |
0.484 |
|
| 2015 |
Burger JA, Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, et al. Adherence To The Ibrutinib 420 mg Dose Administered To Patients With Previously Treated CLL Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.053 |
0.359 |
|
| 2015 |
Brown JJR, Byrd JC, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan S, Jaeger U, Devereux S, Barr PM, Furman R, Kipps T, Cymbalista F, et al. Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial Clinical Lymphoma Myeloma and Leukemia. 15: S204. DOI: 10.1016/J.Clml.2015.04.064 |
0.392 |
|
| 2014 |
Brown JR, O'Brien SM, Barrientos JC, Kay NE, Reddy NM, Coutre SE, Tam C, Mulligan SP, Jäger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Fardis M, et al. Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: LBA7008. PMID 28141976 DOI: 10.1200/Jco.2014.32.18_Suppl.Lba7008 |
0.322 |
|
| 2014 |
Christopherson RI, Mactier S, Almazi JG, Kohnke PL, Best OG, Mulligan SP. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells. Nucleosides, Nucleotides & Nucleic Acids. 33: 375-83. PMID 24940695 DOI: 10.1080/15257770.2013.863334 |
0.716 |
|
| 2014 |
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England Journal of Medicine. 371: 213-23. PMID 24881631 DOI: 10.1056/Nejmoa1400376 |
0.424 |
|
| 2014 |
Mulligan SP, Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerström J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundström G, Johansson H, Brandberg Y, Liliemark J, et al. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leukemia & Lymphoma. 55: 2769-77. PMID 24524339 DOI: 10.3109/10428194.2014.893306 |
0.335 |
|
| 2014 |
Adena M, Houltram J, Mulligan SP, Todd C, Malanos G. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. Pharmacoeconomics. 32: 193-207. PMID 24442832 DOI: 10.1007/S40273-013-0125-7 |
0.393 |
|
| 2014 |
Huang PY, Best OG, Almazi JG, Belov L, Davis ZA, Majid A, Dyer MJ, Pascovici D, Mulligan SP, Christopherson RI. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma. 55: 2085-92. PMID 24289109 DOI: 10.3109/10428194.2013.867486 |
0.602 |
|
| 2014 |
Montillo M, O'Brien S, Tedeschi A, Hillmen P, Dearden C, Gill D, Brown JR, Barrientos JC, Mulligan S, Furman RR, Cymbalista F, Plascencia C, Chang S, Hsu E, James DF, et al. Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report Blood. 124: 5654-5654. DOI: 10.1182/Blood.V124.21.5654.5654 |
0.372 |
|
| 2014 |
Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, et al. Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Blood. 124: 4696-4696. DOI: 10.1182/Blood.V124.21.4696.4696 |
0.353 |
|
| 2014 |
Best OG, Crassini K, O'Neill M, O'Dwyer ME, Mulligan SP. Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia Blood. 124: 4693-4693. DOI: 10.1182/Blood.V124.21.4693.4693 |
0.831 |
|
| 2014 |
Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy N, Coutre S, Tam C, Mulligan S, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, et al. Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Blood. 124: 3331-3331. DOI: 10.1182/Blood.V124.21.3331.3331 |
0.348 |
|
| 2014 |
Crassini K, Stevenson WS, Mulligan SP, Best OG. MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling Blood. 124: 3330-3330. DOI: 10.1182/Blood.V124.21.3330.3330 |
0.838 |
|
| 2014 |
Best OG, Pyke T, Crassini K, Stevenson WS, Mulligan SP. The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment Blood. 124: 3326-3326. DOI: 10.1182/Blood.V124.21.3326.3326 |
0.838 |
|
| 2014 |
Mulligan SP, Gill D, Turner P, Renwick WEP, Latimer M, Mackinlay N, Berkahn L, Simpson D, Campbell P, Forsyth CJ, Cull G, Harrup R, Sulda M, Best G, Bressel M, et al. A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity Blood. 124: 3325-3325. DOI: 10.1182/Blood.V124.21.3325.3325 |
0.314 |
|
| 2014 |
Rawstron A, Fazi C, Villamor N, Delgado J, Letestu R, Cymbalista F, Palacio C, Bosch F, De Tute RM, Liptrot S, O'Brien D, Spacek M, Dobber J, Kater AP, Gambell PC, ... ... Mulligan SP, et al. A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study Blood. 124: 1976-1976. DOI: 10.1182/Blood.V124.21.1976.1976 |
0.341 |
|
| 2014 |
Badoux XC, Best G, Gabrielli S, Hayes M, Zhu Y, Mulligan S, Kuss BJ. Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL) Blood. 124: 1959-1959. DOI: 10.1182/Blood.V124.21.1959.1959 |
0.371 |
|
| 2014 |
Sylvester J, Kumar K, Mulligan S, Ng K. 17. Multifocal central nervous system demyelination with Lhermitte’s phenomenon secondary to chemotherapy Clinical Neurophysiology. 125: e6. DOI: 10.1016/J.Clinph.2013.10.039 |
0.305 |
|
| 2013 |
Huang PY, Kohnke P, Belov L, Best OG, Mulligan SP, Christopherson RI. Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society For Pharmaceutical Sciences, Sociã©Tã© Canadienne Des Sciences Pharmaceutiques. 16: 231-7. PMID 23958192 DOI: 10.18433/J3F01C |
0.652 |
|
| 2013 |
Best OG, Crassini K, Freeman JA, Mulligan SP. The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal of Infectious Diseases. 45: 729. PMID 23826794 DOI: 10.3109/00365548.2013.809477 |
0.788 |
|
| 2013 |
Che Y, Best OG, Zhong L, Kaufman KL, Mactier S, Raftery M, Graves LM, Mulligan SP, Christopherson RI. Hsp90 Inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells. Journal of Proteome Research. 12: 1710-22. PMID 23458665 DOI: 10.1021/Pr301055Y |
0.679 |
|
| 2013 |
Best OG, Mulligan SP. The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulation. Leukemia & Lymphoma. 54: 1123-4. PMID 23134359 DOI: 10.3109/10428194.2012.746685 |
0.646 |
|
| 2013 |
Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson W, Mulligan SP. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia & Lymphoma. 54: 99-104. PMID 22738394 DOI: 10.3109/10428194.2012.706285 |
0.77 |
|
| 2013 |
De Vos S, Sehn LH, Mulligan SP, Dreyling MH, Rummel MJ, Zinzani PL, Johnson DM, Evans S, Dansey RD, Godfrey WR, Czuczman MS. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). Journal of Clinical Oncology. 31: TPS8618-TPS8618. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps8618 |
0.391 |
|
| 2013 |
Crassini K, Stevenson Ws, Mulligan SP, Frcpa. MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162 Blood. 122: 4192-4192. DOI: 10.1182/Blood.V122.21.4192.4192 |
0.801 |
|
| 2013 |
Best G, Gabrielli S, Miss, Zhu Y, Hayes M, Kuss BJ, Stevenson W, Mulligan SP. Genomic Profiling In Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (ALLG CLL5 OFOCIR trial) As Initial Treatment Of Chronic Lymphocytic Leukemia (CLL) Blood. 122: 1624-1624. DOI: 10.1182/Blood.V122.21.1624.1624 |
0.502 |
|
| 2012 |
Best OG, Mulligan SP. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leukemia & Lymphoma. 53: 2314-20. PMID 22646928 DOI: 10.3109/10428194.2012.698278 |
0.709 |
|
| 2012 |
Almazi JG, Mactier S, Best OG, Crossett B, Mulligan SP, Christopherson RI. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics. Clinical Applications. 6: 279-90. PMID 22641291 DOI: 10.1002/Prca.201200003 |
0.626 |
|
| 2012 |
Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, Mulligan SP. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia & Lymphoma. 53: 1367-75. PMID 22149137 DOI: 10.3109/10428194.2011.647310 |
0.721 |
|
| 2012 |
Huang PY, Best OG, Belov L, Mulligan SP, Christopherson RI. Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia & Lymphoma. 53: 1046-56. PMID 22023531 DOI: 10.3109/10428194.2011.631370 |
0.653 |
|
| 2012 |
Mazi JGA, Best OG, Alomari M, Crossett B, Mulligan SP, Christopherson RI. Fludarabine induced changes in p63 and p73 expression and p53 protein binding partners F1000research. 3. DOI: 10.7490/F1000Research.1089937.1 |
0.585 |
|
| 2012 |
Mulligan SP, Gill DS, Turner P, Renwick WEP, Harrup R, Latimer M, Mackinlay N, Berkahn L, Simpson D, Campbell P, Tiley C, Cull G, Collins M, Cortissos P, Sulda M, et al. A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study Blood. 120: 436-436. DOI: 10.1182/Blood.V120.21.436.436 |
0.341 |
|
| 2012 |
Best G, Crassini K, Stevenson W, Mulligan SP. Inhibition of Mitogen Activated Protein Kinase Kinase (MEK1) Is Effective Against CLL Cells Cultured in Media Alone or in a Supportive Microenvironment and Is Synergistic with Fludarabine in a Mechanism That Involves Decreased Levels of Reactive Oxygen Species and MCL-1 Protein Blood. 120: 1804-1804. DOI: 10.1182/Blood.V120.21.1804.1804 |
0.807 |
|
| 2011 |
Henrich S, Mactier S, Best G, Mulligan SP, Crossett B, Christopherson RI. Fludarabine nucleoside modulates nuclear "survival and death" proteins in resistant chronic lymphocytic leukemia cells. Nucleosides, Nucleotides & Nucleic Acids. 30: 1181-9. PMID 22132973 DOI: 10.1080/15257770.2011.603716 |
0.406 |
|
| 2011 |
Mulligan CS, Thomas ME, Mulligan SP. Monoclonal B-lymphocytosis: demographics, nature and subclassification in 414 community patients. Leukemia & Lymphoma. 52: 2293-8. PMID 21756037 DOI: 10.3109/10428194.2011.598250 |
0.358 |
|
| 2011 |
Best G, Mulligan S. 5.42 The Heat Shock Protein 90 Inhibitor AUY922 is Effective in Combination with Fludarabine Against CLL Cells Cultured on a CD40L-Stromal Layer and Inhibits Their Activated/Proliferative Phenotype Clinical Lymphoma Myeloma and Leukemia. 11: S272. DOI: 10.1016/J.Clml.2011.09.196 |
0.396 |
|
| 2011 |
Che Y, Best G, Mirzaei M, Pascovici D, Haynes PA, Mulligan S, Christopherson RI. 5.26 Hsp90 Inhibitor Restores P53-Mutated MEC1 Chronic Lymphocytic Leukemia Cell Sensitivity to Fludarabine by Downregulating DNA Repair and Endoplasmic Reticulum Chaperone Proteins Clinical Lymphoma Myeloma and Leukemia. 11: S260-S261. DOI: 10.1016/J.Clml.2011.09.180 |
0.391 |
|
| 2011 |
Mulligan SP, Gill D, Turner P, Renwick W, Harrup R, Latimer M, Berkahn L, Simpson D, Sulda M, Best G, Kuss B, Cull G. 5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study Clinical Lymphoma, Myeloma & Leukemia. 11. DOI: 10.1016/J.Clml.2011.09.179 |
0.363 |
|
| 2011 |
Huang PY, Best OG, Mactier S, Majid A, Dyer M, Mulligan SP, Christopherson RI. 4.7 Identification of Novel Protein Markers of Progressive Chronic Lymphocytic Leukaemia Clinical Lymphoma Myeloma and Leukemia. 11: S221-S222. DOI: 10.1016/J.Clml.2011.09.127 |
0.642 |
|
| 2011 |
Al-Mazi JG, Best OG, Alomari M, Mulligan SP, Christopherson RI. 2.19 Fludarabine-Induced Changes in p63 and p73 Expression and TP53 Protein Binding in TP53 Wild-Type and Mutated Cell Lines Clinical Lymphoma Myeloma and Leukemia. 11: S171. DOI: 10.1016/J.Clml.2011.09.052 |
0.618 |
|
| 2010 |
Best OG, Singh N, Forsyth C, Mulligan SP. The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway. British Journal of Haematology. 151: 185-8. PMID 20738310 DOI: 10.1111/J.1365-2141.2010.08348.X |
0.701 |
|
| 2010 |
Sasson SC, Smith S, Seddiki N, Zaunders JJ, Bryant A, Koelsch KK, Weatherall C, Munier ML, McGinley C, Yeung J, Mulligan SP, Moore J, Cooper DA, Milliken S, Kelleher AD. IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine. 50: 58-68. PMID 20060740 DOI: 10.1016/J.Cyto.2009.12.001 |
0.327 |
|
| 2010 |
Mulligan SP, Gill DS, Renwick WEP, Sulda ML, Best OG, Kuss BJ, Seymour JF. The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood. 116: 699-699. DOI: 10.1182/Blood.V116.21.699.699 |
0.627 |
|
| 2010 |
Best OG, Mulligan SP. The Hsp90 Inhibitor SNX7081 Restores the Fludarabine Sensitivity of Chronic Lymphocytic Leukemia (CLL) Cells Harbouring Mutations of ATM or TP53 Blood. 116: 2473-2473. DOI: 10.1182/Blood.V116.21.2473.2473 |
0.713 |
|
| 2009 |
Mulligan CS, Thomas ME, Mulligan SP. Lymphocytes, B lymphocytes, and clonal CLL cells: observations on the impact of the new diagnostic criteria in the 2008 Guidelines for Chronic Lymphocytic Leukemia (CLL). Blood. 113: 6496-7; author reply. PMID 19541838 DOI: 10.1182/Blood-2008-07-166710 |
0.381 |
|
| 2009 |
Mulligan CS, Best OG, Mulligan SP. The precursor of chronic lymphocytic leukemia. The New England Journal of Medicine. 360: 2575; author reply 2. PMID 19516039 DOI: 10.1056/NEJMc090559 |
0.615 |
|
| 2009 |
Barber N, Gez S, Belov L, Mulligan SP, Woolfson A, Christopherson RI. Profiling CD antigens on leukaemias with an antibody microarray. Febs Letters. 583: 1785-91. PMID 19298816 DOI: 10.1016/J.Febslet.2009.03.018 |
0.337 |
|
| 2008 |
Mulligan CS, Thomas ME, Mulligan SP. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. The New England Journal of Medicine. 359: 2065-6; author reply. PMID 18987375 DOI: 10.1056/NEJMc086211 |
0.328 |
|
| 2008 |
Henrich S, Gez S, Crossett B, Mulligan SP, Christopherson RI. Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides & Nucleic Acids. 27: 634-40. PMID 18600519 DOI: 10.1080/15257770802142287 |
0.407 |
|
| 2008 |
Freeman JA, Forsyth CJ, Mackinlay NJ, Han P, Mulligan SP. Immunoglobulin G (IgG) Subclasses in Chronic Lymphocytic Leukaemia Blood. 112: 4180-4180. DOI: 10.1182/Blood.V112.11.4180.4180 |
0.343 |
|
| 2008 |
Mulligan CS, Thomas ME, Mulligan SP. Monoclonal B-Lymphocytosis: Analysis of the Incidence, Demographics, Nature and Subclassification in 414 Patients Blood. 112: 3129-3129. DOI: 10.1182/Blood.V112.11.3129.3129 |
0.371 |
|
| 2007 |
Mulligan SP. Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardy. Leukemia & Lymphoma. 48: 1885-7. PMID 17917953 DOI: 10.1080/10428190701599013 |
0.33 |
|
| 2007 |
Karlsson KA, Strömberg M, Jönsson V, Mulligan SP, Liliemark J, Juliusson G. Cladribine (CdA) Gives Longer Response Duration Than Fludarabine (F) and High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia (CLL). First Results from the International Randomized Phase III Trial. Blood. 110: 630-630. DOI: 10.1182/Blood.V110.11.630.630 |
0.308 |
|
| 2006 |
Belov L, Mulligan SP, Barber N, Woolfson A, Scott M, Stoner K, Chrisp JS, Sewell WA, Bradstock KF, Bendall L, Pascovici DS, Thomas M, Erber W, Huang P, Sartor M, et al. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology. 135: 184-97. PMID 16939496 DOI: 10.1111/J.1365-2141.2006.06266.X |
0.417 |
|
| 2005 |
Belov L, Huang P, Chrisp JS, Mulligan SP, Christopherson RI. Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods. 305: 10-9. PMID 16125720 DOI: 10.1016/J.Jim.2005.07.007 |
0.421 |
|
| 2005 |
Woolfson A, Stebbing J, Tom BD, Stoner KJ, Gilks WR, Kreil DP, Mulligan SP, Belov L, Chrisp JS, Errington W, Wildfire A, Erber WN, Bower M, Gazzard B, Christopherson RI, et al. Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals. Blood. 106: 1003-7. PMID 15827132 DOI: 10.1182/Blood-2004-12-4642 |
0.335 |
|
| 2005 |
Wierda WG, Mulligan S, Shelvin B, Belov L, Rassenti L, Kipps T, Lerner S, Thomas M, Kantarjian H, Keating M. Surface Antigens Identified by Antibody Microarray That Correlate with IgVH Mutational Status and ZAP70 Expression in CLL. Blood. 106: 2944-2944. DOI: 10.1182/Blood.V106.11.2944.2944 |
0.344 |
|
| 2004 |
Wilson PK, Mulligan SP, Christopherson RI. Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin. Leukemia Research. 28: 725-31. PMID 15158094 DOI: 10.1016/J.Leukres.2003.11.013 |
0.475 |
|
| 2004 |
Karlsson K, Strömberg M, Jönsson V, Gill D, Hammerström J, Wallvik J, Mulligan S, Bradstock K, Liliemark J, Juliusson G. Cladribine (CdA) or Fludarabine (F) or High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia? First Interim Analysis of Data from the International Randomized Phase III Trial. Blood. 104: 3470-3470. DOI: 10.1182/Blood.V104.11.3470.3470 |
0.326 |
|
| 2003 |
Belov L, Huang P, Barber N, Mulligan SP, Christopherson RI. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics. 3: 2147-54. PMID 14595814 DOI: 10.1002/Pmic.200300599 |
0.346 |
|
| 1999 |
Chen JR, Gu BJ, Dao LP, Bradley CJ, Mulligan SP, Wiley JS. Transendothelial migration of lymphocytes in chronic lymphocytic leukaemia is impaired and involved down-regulation of both L-selectin and CD23. British Journal of Haematology. 105: 181-9. PMID 10233382 DOI: 10.1111/J.1365-2141.1999.01278.X |
0.38 |
|
| 1998 |
Wilson PK, Szabados E, Mulligan SP, Christopherson RI. Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines. The International Journal of Biochemistry & Cell Biology. 30: 833-42. PMID 9722988 DOI: 10.1016/S1357-2725(98)00024-7 |
0.386 |
|
| 1998 |
Weston KM, Mulligan SP, Raison RL. In vivo binding of mouse IgG via polyreactive surface IgM abrogates progressive lymphocytosis in prolymphocytic leukemia. Leukemia & Lymphoma. 29: 361-73. PMID 9684933 DOI: 10.3109/10428199809068572 |
0.377 |
|
| 1992 |
Mulligan SP, Catovsky D. Splenic Lymphoma with Villous Lymphocytes Leukemia & Lymphoma. 6: 97-105. DOI: 10.3109/10428199209064885 |
0.373 |
|
| 1990 |
Mulligan SP, Wills EJ, Young GA. Exercise-induced CD8 lymphocytosis: a phenomenon associated with large granular lymphocyte leukaemia. British Journal of Haematology. 75: 175-80. PMID 2115372 DOI: 10.1111/J.1365-2141.1990.Tb02645.X |
0.316 |
|
| Show low-probability matches. |